

Haematologica
HAEMATOL/2018/214122
Version 3

MYD88 mutations identify a molecular subgroup of diffuse large B-cell
lymphoma with an unfavourable prognosis

Joost S. Vermaat, Sebastiaan F. Somers, Liesbeth C. de Wreede,
Willem Kraan, Ruben A.L. de Groen, Anne M.R. Schrader, Emile D.
Kerver, Cornelis G. Scheepstra, Henriëtte Beerenschot, Wendy Deenik,
Jurgen Wegman, Rianne Broers, Jan-Paul D. de Boer, Marcel Nijland,
Tom van Wezel, Hendrik Veelken, Marcel Spaargaren, Arjen H.
Cleven, Marie José Kersten, and Steven T. Pals

Disclosures: Conflicts of interest: M.J.K. and M.N. have received honoraria/research funding from Kite Pharma, Millennium/Takeda, Mundipharma, Gilead Sciences, Bristol-Myers Squibb, Roche, Celgene, Novartis Pharmaceuticals Corporation, Merck Sharp & Dohme, and Amgen. M.S. received research funding from Pharmacyclics and Johnson&Johnson. The other authors do not have any conflicts of interests or disclosure to declare: J.S.V., S.F.S., L.C.W., W.K., R.A.G., A.M.S., E.D.K., H.B., W.D., J.W., R.B., J.D.B., M.N., T.W., H.V., A.H.C and S.T.P.

Contributions: Authorship contribution: J.S.V., S.F.S., L.C.W., R.A.G., A.M.S., H.V., M.S., A.H.C., M.J.K. and S.T.P. contributed to the design of the research; J.S.V., W.K., E.D.K., C.G.S., H.B., W.D., J.W., R.B., J.D.B., M.N., H.V., A.H.C., M.J.K., and S.T.P. contributed to the collection of patient material; J.S.V., S.F.S., W.K., L.C.W., R.A.G., A.M.S., E.D.K., C.G.S., H.B., W.D., J.W., R.B., J.P.B., M.N., T.W., H.V., M.S., A.H.C., M.J.K. and S.T.P., contributed to the analysis of the data; and J.S.V., S.F.S., L.C.W., R.A.G., A.M.S., M.N., T.W., H.V., A.H.C., M.J.K., and S.T.P. contributed to the writing of the manuscript.